The popular COVID-era stock that soared 900% in less than a year

Moderna's stock surged 14% on Friday on Wall Street to $225, amid its inclusion in the Nasdaq 100 index and anticipation of Phase 3 trial data for melanoma treatment. The stock has completed an extraordinary rise of about 900% from a low of $22 in November 2025. However, the average target price of 18 analysts stands at $122 – 46% below the current price.

Moderna (MRNA) shares surged about 14% on Wall Street last Friday, reaching $225 per share. The gains come amid the company's inclusion in the Nasdaq 100 index and anticipation of advanced data from a Phase 3 trial for melanoma treatment. This completes an extraordinary rise of about 900% from the stock's low point in November 2025, when it traded at just $22. Moderna made headlines during the COVID-19 pandemic with its mRNA-based vaccine. In August 2021, its market cap reached about $167 billion, but it later weakened sharply, and by November 2025, the company's value had fallen below $10 billion. Since then, the stock has recovered, surging over 170% in a single day on August 18 after the company reported positive results from a personalized mRNA cancer vaccine trial. Despite the sharp rise, the current stock price is significantly higher than analyst forecasts. 18 analysts set target prices ranging from $40 to $200, with an average of about $122 – 46% below the current price. The article notes that the trend's continuation will depend on clinical trial results and the company's ability to turn developments into commercial products.